Table 3.
Epithelial ovarian cancer | Diagnostic criteria (%) | VEGF | HE4 | CA125 | VEGF + HE4 | VEGF + CA125 | HE4+ CA125 | VEGF + HE4 + CA125 |
---|---|---|---|---|---|---|---|---|
I stage |
Sensitivity |
44 |
44 |
40 |
76 |
72 |
72 |
84 |
Specificity |
94 |
94 |
92 |
88 |
88 |
88 |
82 |
|
PV-PR |
78 |
78 |
71 |
76 |
75 |
75 |
70 |
|
|
PV-NR |
77 |
77 |
75 |
88 |
86 |
86 |
91 |
II stage |
Sensitivity |
48 |
28 |
64 |
64 |
76 |
80 |
96 |
Specificity |
94 |
94 |
92 |
88 |
88 |
88 |
82 |
|
PV-PR |
75 |
70 |
80 |
72 |
76 |
76 |
72 |
|
|
PV-NR |
74 |
72 |
83 |
83 |
88 |
89 |
97 |
III stage |
Sensitivity |
72 |
68 |
80 |
88 |
92 |
88 |
96 |
Specificity |
94 |
94 |
92 |
88 |
88 |
88 |
82 |
|
PV-PR |
85 |
85 |
83 |
78 |
79 |
78 |
72 |
|
|
PV-NR |
87 |
85 |
90 |
93 |
95 |
93 |
97 |
IV stage |
Sensitivity |
40 |
80 |
84 |
88 |
92 |
92 |
96 |
Specificity |
94 |
94 |
92 |
88 |
88 |
88 |
82 |
|
PV-PR |
76 |
86 |
84 |
78 |
79 |
95 |
72 |
|
|
PV-NR |
75 |
85 |
92 |
93 |
95 |
79 |
97 |
Total group |
Sensitivity |
48 |
55 |
67 |
81 |
83 |
83 |
93 |
Specificity |
94 |
94 |
92 |
88 |
88 |
88 |
82 |
|
PV-PR |
94 |
94 |
94 |
93 |
93 |
93 |
91 |
|
|
PV-NR |
47 |
51 |
58 |
69 |
72 |
72 |
85 |
Serous epithelial |
Sensitivity |
46 |
70 |
64 |
81 |
77 |
88 |
94 |
Specificity |
94 |
94 |
92 |
88 |
88 |
88 |
82 |
|
PV-PR |
89 |
88 |
92 |
88 |
87 |
88 |
95 |
|
|
PV-NR |
71 |
74 |
71 |
81 |
78 |
88 |
93 |
Endometrioid epithelial |
Sensitivity |
50 |
36 |
69 |
71 |
91 |
80 |
95 |
Specificity |
94 |
94 |
92 |
88 |
88 |
88 |
82 |
|
PV-PR |
88 |
80 |
91 |
84 |
87 |
86 |
83 |
|
PV-NR | 67 | 61 | 77 | 77 | 93 | 83 | 95 |